A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy

Shanxi Kangbao Biological Product Co., Ltd.1 个研究点分布在 1 个国家目标入组 46 人开始时间: 2021年1月23日最近更新: 2026年5月11日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 46
试验地点: 1
主要终点: Pharmacokinetics：Cmax

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 60 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Male or female aged from 18 to 60 (include 18 and 60)；
•Body mass index (BMI) [weight (kg)/ height 2(m2)] is from 18.0 to 26.0（include 18.0 and 26.0），male weight≥50kg，female weight≥45kg；
•Confirmed HIV-1 infection；
•HIV viral load ≥ 1000 copies/mL；
•Patients who have no birth plan within 2 weeks before the screening and 3 months after the end of the trial, consenting to take effective non-drug contraceptive measures during the trial period；
•Understand the purpose of and procedures required for the study and having confirmed they are willing to participate in the study by signing the informed consent document.

排除标准

•Patients in the acute infection stage;
•Confirmed AIDS patients；
•Patients who have received antiviral therapy and/or have been vaccinated against HIV；
•HBsAg is (+), and/or anti-HCV is (+)；
•Abnormal liver function tests (ALT and / or AST> 3ULN, or total bilirubin> 2ULN)；
•Glomerular filtration rate <70mL/min/1.73m2, or creatinine ≥ULN；
•Patients who is currently suffering from a more serious chronic diseases, metabolic diseases (such as diabetes), neurological and mental diseases；
•Patients who have previous history of pancreatitis；
•Females who are pregnant or breastfeeding, or females of childbearing age who are unable to take contraception as required;
•Allergic constitution or known allergy to the components of study drug；
•With a history of smoking addiction within 12 months before screening (average number≥5 cigarettes per day)；
•With a history of alcohol abuse within 12 months before screening (average drinking≥14 units of alcohol per week: 1 unit = 285mL beer, 25mL spirits, or 150mL wine) or those who have a positive alcohol breath test before enrollment；
•With a history of drug abuse within 12 months before screening or those who tested positive for addictive substances before enrollment；
•Patients who have participated in other investigational drug study within 3 months before screening (except for traditional Chinese medicine）；
•Other factors that the investigators consider unsuitable for the trial.